Covered recipient · General Payments record
LARA FARHAT
Allopathic & Osteopathic Physicians Allergy & Immunology
General Payments · PY2019–2024
$2,405.54
- Reported across 77 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $394.47 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Kaleo, Inc. | $124.97 | 1 |
| ABBVIE INC. | $82.44 | 5 |
| Incyte Corporation | $48.32 | 3 |
| Genentech USA, Inc. | $36.05 | 2 |
| Galderma Laboratories, L.P. | $33.86 | 2 |
| Blueprint Medicines Corporation | $18.31 | 1 |
| Amgen Inc. | $17.75 | 1 |
| OptiNose US, Inc. | $16.92 | 1 |
| GENZYME CORPORATION | $15.85 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $15.07 | 10/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103710533 | CMS |
| ABBVIE INC. | $17.72 | 10/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103710535 | CMS |
| ABBVIE INC. | $18.15 | 10/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103710537 | CMS |
| ABBVIE INC. | $15.60 | 10/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103710539 | CMS |
| ABBVIE INC. | $15.90 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103710541 | CMS |
| Amgen Inc. | $17.75 | 12/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111572540 | CMS |
| Blueprint Medicines Corporation | $18.31 | 11/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147448382 | CMS |
| Galderma Laboratories, L.P. | $15.41 | 10/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145296849 | CMS |
| Galderma Laboratories, L.P. | $18.45 | 10/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145296851 | CMS |
| Genentech USA, Inc. | $16.90 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133051048 | CMS |
| Genentech USA, Inc. | $19.15 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133051052 | CMS |
| GENZYME CORPORATION | $15.85 | 10/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139859748 | CMS |
| Incyte Corporation | $15.38 | 10/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141221332 | CMS |
| Incyte Corporation | $14.61 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141260305 | CMS |
| Incyte Corporation | $18.33 | 12/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141172153 | CMS |
| kaleo, Inc. | $124.97 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126627147 | CMS |
| Optinose US, Inc. | $16.92 | 09/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142170270 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.